Interferon beta-1b is effective in Japanese RRMS patients

Saida, Takahiko; Tashiro, Kunio; Itoyama, Yasuto; Sato, Tomoo; Ohashi, Yozo; Zhao, Zhenming

doi:10.1212/01.wnl.0000151856.10387.e2

Cited by 95 publications

(84 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients were randomized into two subgroups and received 50 µg or 250 µg (n = 96 in each subgroup) subcutaneous IFN-β 1b every other day for up to 2 years (Saida et al 2005). Patients in both groups were tested for NAbs using the CPE assay.…”

Section: Discussionmentioning

confidence: 99%

Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients

Sato

Nakashima

Fukazawa

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system. Interferon-β (IFN-β) has been used as the first line therapy for MS treatment in Japan, but patients treated with IFN-β may develop antibodies, known as neutralizing antibodies (NAbs), which abrogate its therapeutic effects. Intramuscular IFN-β 1a and subcutaneous IFN-β 1b are currently available in Japan, but large-scale studies evaluating the prevalence and clinical implications of NAbs against these IFN-β preparations in MS patients have only been performed in Caucasian populations. NAbs positivity has been reported to be associated with HLA-DRB1 alleles, suggesting that the positivity might differ among populations with distinct genetic backgrounds. Clinical information and sera were collected from 229 consecutive MS patients treated with IFN-β in 4 centers in Japan. Sera were tested for NAbs using a luciferase reporter gene assay. In total, 5.2% of IFN-β-1a-treated patients (4/77) and 30.3% of IFN-β-1b-treated patients (46/152) were positive for Nabs. The frequency of NAbs was highest in patients treated for 13 to 24 months. Clinical relapse and contrast-enhancing lesions in the magnetic resonance imaging increased together with NAbs titers in this group. In conclusion, the prevalence of NAbs in Japanese MS patients is similar to that in Caucasian populations and is associated with an increase in disease activity. Therefore, routine NAbs testing is recommended also in Asian populations to ensure the early identification of patients who would benefit from a change in therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients

Sato

Nakashima

Fukazawa

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…A recent report indicated that interferon beta-1b benefited Japanese remitting relapsing multiple sclerosis patients. Subgroup analyses suggested that the magnitude and direction of treatment effect in patients with OSMS and MS was similar, albeit not significant because of small sample size (60). However, the results of this study on the efficacy of beta-interferon efficacy in NMO patients were limited because of the fact that the trial was not powered to specifically evaluate the OSMS subgroup.…”

Section: Prevention Of Relapsesmentioning

confidence: 79%

Neuromyelitis optica: a distinct demyelinating disease of the central nervous system

Argyriou

Makris

2008

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

“…A previous Japanese clinical trial of IFNβ-1b in MS showed that ARR in "then OSMS" declined after therapy, but the difference was not statistically significant (Saida et al 2005). Those patients with "OSMS" were perhaps the mixture of MS with optic-spinal presentation and NMO.…”

Section: Discussionmentioning

confidence: 92%

Therapeutic Efficacy of Interferon .BETA.-1b in Japanese Patients with Optic-Spinal Multiple Sclerosis

Shimizu

Fujihara

Kubo

et al. 2011

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Optic neuritis and myelitis are manifestations in both multiple sclerosis (MS) and neuromyelitis optica (NMO). But unlike MS, NMO is characterized by severe optic neuritis, longitudinally extensive and transverse myelitis, and the presence of aquaporin-4 antibody. Since patients with optic neuritis and myelitis have often been diagnosed with "optic-spinal MS (OSMS)" in Asia, it was obscure whether "OSMS" is synonymous with NMO or includes both NMO and MS. Interferon β (IFNβ)-1a and -1b are used as the first-line disease-modifying therapy for MS. However, some neurologists have been reluctant to use IFNβ to treat patients with optic-spinal symptoms, because IFNβ therapy is not efficacious in NMO. To evaluate the therapeutic effect of IFNβ in patients with ''genuine'' OSMS, we retrospectively evaluated Japanese MS patients who fulfilled the following six criteria: 1) Relapsing-remitting MS with optic-spinal presentation alone (no brain symptoms), 2) With or without asymptomatic brain MRI lesions, 3) Oligoclonal IgG bandpositive, 4) aquaporin-4 antibody seronegativity, 5) No myelitis extending longitudinally over ≥ 3 vertebral segments, and 6) Duration of IFNβ-1b therapy ≥ 2 years. Among 157 patients with MS, six (four women and two men, age 43.8 ± 8.5 years old) met all the criteria. Their Expanded Disability Status Scale scores were lowered (4.1 ± 2.4 → 3.1 ± 2.8) (P = 0.033) and annualized relapse rate was decreased (0.59 ± 0.34 → 0.13 ± 0.15) (P = 0.027) after IFNβ-1b therapy. These results suggest that IFNβ is therapeutically effective in inhibiting functional worsening and reducing relapse rate in ''genuine'' OSMS.

show abstract

Interferon beta-1b is effective in Japanese RRMS patients

Cited by 95 publications

References 34 publications

Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients

Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients

Neuromyelitis optica: a distinct demyelinating disease of the central nervous system

Therapeutic Efficacy of Interferon .BETA.-1b in Japanese Patients with Optic-Spinal Multiple Sclerosis

Contact Info

Product

Resources

About